Still no benefit of MitraClip in MITRA-FR

Nature Reviews Cardiology, Published online: 16 September 2019; doi:10.1038/s41569-019-0280-4The 2-year results of the MITRA-FR trial confirm the 1-year findings showing that addition of percutaneous mitral valve repair to medical treatment does not reduce the risk of death or hospitalization for heart failure compared with medical treatment alone in patients with heart failure and severe secondary mitral regurgitation
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research

Related Links:

Last month, Medtronic announced receipt of U.S. Food and Drug Administration (FDA) approval for and launch of the Evolut Pro+ TAVR (Transcatheter Aortic Valve Replacement) System to treat patients with symptomatic severe aortic stenosis. Aortic steno...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Exclusive Source Type: blogs
A stronger and more experienced Ancora Heart entered into the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation this past week. The private company – which is poised to take on medtech giants Abbott Laboratories and Edwards Lifesciences in the functional mitral regurgitation (FMR) space, presented even more data than it did last year at TCT. “There’s a big presence for us this year [at TCT] with three different presentations,” Jeff Closs, president and CEO of Ancora Heart, to...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Business Source Type: news
Abstract Background: The COAPT trial demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) using the MitraClip resulted in reduced mortality and heart-failure hospitalizations and improved quality of life when compared with maximally-tolerated guideline-directed medical therapy (GDMT) in heart-failure patients with 3-4+ secondary mitral regurgitation (SMR). Whether TMVr is cost-effective compared with GDMT in this population is unknown. Methods: We used data from the COAPT trial to perform a formal, patient-level economic analysis of TMVr + GDMT vs. GDMT alone for patients with heart failure and ...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Patients with symptomatic heart failure (HF), reduced left ventricular ejection fraction (LVEF), and high-grade functional mitral regurgitation (MR) may benefit from percutaneous edge-to-edge mitral valve repair (PMVR). However, patient selection still remains a central issue. We sought to investigate the potential role of the global longitudinal strain- (GLS-) based left ventricular contractile reserve (LVCR) at dobutamine stress echocardiography (DSE) in this setting.
Source: Journal of the American Society of Echocardiography - Category: Cardiology Authors: Source Type: research
CONCLUSIONS: MitraClip procedure improved life-years and quality of life in patients at high surgical risk and it was also a cost-effective treatment option. PMID: 31516049 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
CONCLUSIONS: A small cohort of patients demonstrated with an elevated TVG higher than 3 mmHg at discharge. This elevation had no impact on clinical improvement, on mortality and hospitalization for heart failure. PMID: 31498114 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
AbstractPurpose of ReviewFunctional mitral regurgitation (FMR) occurs when mitral leaflets are prevented from adequate coaptation by underlying left ventricular (LV) dysfunction, mitral annular dilation, or both. This review aims to clarify the complex clinical issues in FMR, including diagnosis and therapy.Recent FindingsEven mild FMR has been shown to affect survival negatively. FMR is a dynamic condition and can vary within systole and with altered loading conditions. An integrative approach, including qualitative and quantitative echocardiographic data, is mandatory to determine severity of FMR. Treatment of FMR starts...
Source: Current Cardiovascular Risk Reports - Category: Cardiology Source Type: research
AbstractPurpose of reviewTranscatheter edge-to-edge mitral valve repair (TMVr) has been increasingly used in the treatment of patients with severe symptomatic mitral regurgitation who are at high or prohibitive risk for surgical intervention. Pre-existing pulmonary hypertension is known to pertain worse prognosis for patients who are undergoing surgical intervention. The aim of this review is to discuss the current literature on the effects of pulmonary hypertension on the transcatheter edge-to-edge mitral valve repair outcomes.Recent findingsLarge registry data in patients undergoing TMVr for treatment of severe mitral re...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Abbott Laboratories’ latest pivotal trial will have the company taking a deeper dive into the treatment of what has been dubbed by some as the “forgotten valve.” The Abbott Park, IL-based has launched an IDE study of the TriClip, a transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation (TR). The TRILUMINATE Pivotal trial will evaluate a catheter-based, non-surgical treatment for patients with severe TR – a condition in which the valve doesn't close properly, allowing blood to flow backward into the heart, which ...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news
Authors: Vogelhuber J, Weber M, Sinning JM, Nickenig G Abstract After aortic valve stenosis, mitral regurgitation (MR) is the second most common valvular disease, particulary affecting older patients. Optimal medical treatment within the context of heart failure therapy is the favored first-line therapy for secondary MR. If symptoms persist despite optimal medical therapy, surgical or transcatheter mitral valve repair is indicated (recommendation class IIb). In contrast, surgical treatment is essential for patients with symptomatic primary MR and left-ventricular ejection fraction (LVEF)>30% and justifiable peri...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
More News: Cardiology | Gastroschisis Repair | Heart | Heart Failure | Heart Valve Surgery